Search

In its efforts to faces the challenges of emerging from the crisis, the EU tries to put the European economies on a sustainable growth path through the 2014-2020 Common Strategic Framework (CSF), sought as an instrument for implementing the Europe 2020 Strategy. According to the CSF thematic objectives, the European Commission proposed for 2014-2020 a new Multiannual Financial Framework, through which thematic concentration and performance incentives are expected to result in more effective spending. The CSF Funds will provide an important source of public investments not only in growth and jobs but in areas supporting them, such as environment protection or resource efficiency. The paper offers a insight of the financing of environmental projects in Romania in the frame of the new Programming period and according to the EU Cohesion Policy objectives for 2014-2020. According to the learned lesson from the previous programming period, for a successful implementation of CSF Funds, with an optimal impact, an appropriate policy and a legal and administrative framework in place are needed.

Agile Model Driven Architecture (MDA) software development processes apply agile principles in the context of executable models. In this paper we present an agile MDA approach for constructing, running, and testing executable UML service-oriented components. This work is part of a series referring to COMDEVALCO - a framework for Software Component Definition, Validation, and Composition.

Purpose The study objective was to compare the overall survival (OS) of patients with unresectable or metastatic hepatocellular carcinoma (HCC) treated with nolatrexed (NOL) or doxorubicin (DOX). Patients and Methods Patients from North America, Europe, and South Africa (N = 445) with HCC were randomly assigned to receive NOL or DOX. Eligible patients had Karnofsky performance status (KPS) ≥ 60%, Cancer of the Liver Italian Program (CLIP) score ≤ 3, and adequate organ function. Primary end point was OS. Secondary end points included progression-free survival (PFS), objective response rates, and safety. The treatment groups were well-balanced with regards to age, sex, ethnic origin, and underlying liver disease. Randomization was stratified according to KPS and CLIP score. Results At the time of the final analysis, 377 patients had died. Median OS was 22.3 weeks for NOL and 32.3 weeks for DOX (P = .0068). The hazard ratio was 0.753 in favor of DOX. Objective response rate (complete response [CR] plus partial response [PR]) was 1.4% for NOL and 4.0% for DOX. Median PFS was 12 weeks for NOL and 10 weeks for DOX (P = .7091). Median time to treatment failure was 8.4 weeks for NOL and 9.1 weeks for DOX (P = .0969). Grade 3 and 4 stomatitis, vomiting, diarrhea, and thrombocytopenia were more common in the NOL arm. Alopecia was more common in the DOX arm. More patients were withdrawn from study for toxicity in the NOL arm than in the DOX arm. Conclusion NOL showed minimal activity in this phase III trial. Further exploration at this dose and schedule in HCC is not warranted.